APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact Point for Italy, “Part of this presentation is taken from the official material produced by EC, DG Research, Unit F”.

AGENDA PRESENTAZIONE APRE SETTIMO PROGRAMMA QUADRO (7PQ) Structure and scope of Health theme Basic principles Health 2013 Work programme key features / priorities How to find partners Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH, ENV… Other funding opportunities for health researchers Information sources

L' APRE è un Ente di ricerca non profit con obiettivo, sancito dall’articolo 3 del suo statuto, di promuovere la partecipazione italiana ai programmi di ricerca e sviluppo finanziati dalla Commissione Europea. Prima realtà del suo genere in Italia, APRE nasce nel 1989 come “Task Force” del Ministero dell’Università e della Ricerca. Nel 1990 viene poi costituita formalmente da Confindustria, ENEA, FAST e Mondimpresa È sostenuta da numerose Università e organizzazioni private e pubbliche del mondo accademico, dell’industria e della finanza. [COS’É APRE?]

Migliorare la “Qualità” della partecipazione italiana nei programmi europei di ricerca su sviluppo e innovazione. Per conto del Ministero dell'Università e della Ricerca (MIUR), APRE ha lo scopo di fornire informazioni, supporto e assistenza sulle modalità di partecipazione ai programmi europei di ricerca e sviluppo tecnologico, ad enti pubblici, enti privati e persone fisiche. Ospita la rete dei National Contact Point (NCP). Assistenza Formazione Informazione [MISSION]

[INTERLOCUTORI] Soci APRE Un po’ di numeri: 110 Soci di cui: 6 associazioni di categoria 34 enti di ricerca tra pubblici e privati 4 realtà appartenenti al mondo della finanza 5 organismi del sistema camerale 4 parchi scientifici 6 enti della pubblica amministrazione 51 università APRE Associazioni industiali Camere di Commercio Parchi Scientifici Università Centri di ricerca Industrie Enti pubblici Finanza Soci APRE [INTERLOCUTORI]

[RISORSE APRE – SPORTELLI LOCALI] Per rafforzare il sistema della cooperazione tra istituzioni pubbliche e private attive nel settore della ricerca scientifica e tecnologica e promuovere e diffondere la ricerca europea a livello nazionale, APRE dispone di una rete di Sportelli regionali. Gli Sportelli, oltre a fornire tutti i servizi specifici dell'APRE, costituiscono anche una sede per favorire le iniziative promosse dai Soci APRE presenti nella regione, supportando inoltre quelle portate avanti da parte di altre istituzioni ed organizzazioni impegnate nel campo della ricerca e dell'innovazione tecnologica Ospitati e gestiti dai Soci APRE, gli Sportelli APRE sono punti di accesso alle informazioni ad operatività regionale e coordinati dalla sede centrale a Roma. [RISORSE APRE – SPORTELLI LOCALI]

partecipazione ad eventi e giornate informative APRE BRUSSEL offre ai soci: partecipazione ad eventi e giornate informative diffusione di informazioni aggiornate sulle politiche, iniziative ed opportunità sulla ricerca in Europa collegamento diretto con vari attori della ricerca Europea (Istituzioni Europee, liaison office e organismi di ricerca degli Stati Membri, Confederazioni e Consorzi paneuropei) accompagnamento agli incontri con i funzionari della Commissione Europea la sala riunione per meeting internazionali dei progetti Europei di ricerca [RISORSE APRE – SPORTELLO EUROPA]

Rappresentanza Italiana Commissione Europea Rappresentanza Italiana Delegati Nazionali PQ MIUR APRE (NCP) 1 In qualità di ente ospitante dei NCP, punti di contatto nazionale per il PQ, lavoriamo a servizio della CE che ci forma, coordinati dal MIUR, con i delegati del PQ tra le altre cose, per le attività di raccolta dei contributi scientifici dalla comnunità scientifica trasmessi poi alla Rappresentanza Ita. [MISSION]

IN ITALIA: COMITATO DI PROGRAMMA SALUTE PUNTI DI CONTATTO NAZIONALI Caterina Buonocore APRE Silvio Garattini (Mario Negri) Stefano Vella (ISS) Caterina Buonocore (APRE) Bruno Mourenza APRE Alfredo Cesario (IRCSS)

[MISSION] Proposta vincente APRE ospita i Punti di contatto nazionale del VII Programma Quadro in Italia. Questi sono nominati dal Ministero dell'Università e della Ricerca (MUR) e riconosciuti dalla Commissione Europea. Informazione Conferenze News Alert Sito web ( www.apre.it) Pubblicazioni Assistenza Informazione Formazione Essere un buon coordinatore Preparazione della proposta Come disseminare i risultati della ricerca Proprietà intellettuale e Consortium Agreement Formazione Supporto prima dell’inizio del progetto (telefono, mail e incontri) Identificazione del tema e del topic FP7 Verificare l’elegibilità della proposta Pre-screening della proposta Aiuto nell‘utilizzo dell’EPSS System Proposta vincente Supporto dopo l’inizio del progetto (telefono, mail e incontri) Negoziazione Management del progetto Disseminazione dei risultati Reporting [MISSION]

COME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO SALUTE NEL 7 PQ COME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO

The 7th Framework programme (FP7) Structure and scope of Health theme Basic principles Health 2013 Work programme key features / priorities Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH… Other funding opportunities for health researchers Information sources

EU research policy Why ? How ? to improve quality of life and to improve competiveness of Europe through collaboration How ? by pooling resources (funds for Framework Programme) by coordinating national research programmes

Associazioni di pazienti Università Centri di ricerca PMI Interlocutori Ospedali Industria Ricerca clinica IRCCS Associazioni di pazienti [INTERLOCUTORI SALUTE]

Joint Research Centre (non-nuclear) FP7 + JRC Joint Research Centre (non-nuclear) + Euratom Euratom © Fit for Health, 2012

R&D Chain © Fit for Health, 2012

EUROPEAN COMMISSION - Research DG 7th Framework Programme for Research Indicative breakdown (€ million) EUROPEAN COMMISSION - Research DG

Collaborative research in the Health theme Main policy drivers: Improving health of European citizens Increasing competitiveness of European health-related industries and businesses Addressing global health issues, including emerging epidemics Budget: €6.1 billion over 7 years (2007-2013)

Collaborative research across borders and other barriers between countries: at least 3 partners from the 27 EU Member States: Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Rumania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom. or the 12 Associated Countries: Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey. In addition, researchers from anywhere in the world can participate: eg: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, … and in many cases, can be funded.

Collaborative research across borders and other barriers between countries but also: between different types of organizations Public & private sector: universities, research centres, large companies, small and medium-sized enterprises (SMEs), etc. between disciplines: multidisciplinary, translational R&D

1. Structure and scope of Health theme

The Health Theme Three main activities (“pillars”) Activity 1: Biotechnology, generic tools & technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care The Innovative Medicines Initiative cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues Activity 4: Support actions & response to policy needs

EC Funding Strategy Translational research Clinical capacity Discovery Research Grants Product development, PPP Discovery Preclinical Phase I/IIa Phase II + III Regulatory Large Collaborative Projects EDCTP Translational research Clinical capacity Bottlenecks = Innovative Medicine Initiative (IMI)

Industry (esp. SME) participation & International Cooperation Policy aspects Industry (esp. SME) participation & International Cooperation Emphasis and special measures for: Small & Medium-sized Enterprises (SMEs) Opportunities and support measures International Cooperation the possibility to tackle issues on a global scale an opportunity to extend your networks beyond Europe

2. Basic Principles

Submission & evaluation Basic principles: Annual calls for proposals (2-stage) Evaluation by panels of independent experts overseen by Independent Observers 3 criteria: Science & Technology excellence Implementation & Management Potential Impact Feedback: Evaluation Summary Reports (ESRs) Experts wanted ! Aim: to fund the best R&D proposals

3. HEALTH 2013 Work Programme

Note: there are some exceptions to the ceilings. Funding schemes for these calls Note: there are some exceptions to the ceilings.

Priorities for Health in 2012-2013 2013 thematic priorities: Brain research Anti-microbial resistance Comparative effectiveness (CER) Cross-cutting priorities: Translation of results into applications Innovation & SMEs Social innovationSocial innovation refers to new strategies, concepts, ideas and organizations that meet social needs of all kinds - from working conditions and education to community development and health - and that extend and strengthen civil society. International cooperation

HEALTH FP7-HEALTH-2013-INNOVATION-1 as main call with an indicative budget of EUR 680 million with broader topics of which many are tailored for SME participation (bottom-up with a minimum percentage of EU funding requested going to SMEs) FP7-HEALTH-2013-INNOVATION-2 as a specific call to boost SME participation for innovative solutions in the health sector with an indicative budget of EUR 140 million. This call has very specific conditions. Maximum project duration is limited to 3 years. 2 STAGE EVALUATION. Max 6 pagine: 1.1 Concept and objectives 1.2 Progress beyond the state-of-the-art 1.3 S/T methodology and associated work plan 2.1 Expected impacts

7th CALL HEALTH Call identifier: FP7-HEALTH-2013-INNOVATION-1 35 topics Proposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 02 October 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 680 million from the 2013 budget Call identifier: FP7-HEALTH-2013-INNOVATION-2 2 topics Proposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 25 September 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 140 million from the 2013 budget

2013 WP preparation Milestones and meetings Roadmap discussed at PC meeting: 5 September 2011 Draft WP v1 (“Orientation paper”) => sent to PC by mid-October Meeting with Advisory Group (9 Nov 2011) PC meeting (9-10 Nov 2011) to discuss draft WP v1 PC meeting (14 Feb. 2012) to discuss draft WP v2 => final input by 24 February Internal draft must be ready by 12 March. Inter-service Consultation (April-May 2012) - draft WP v3 Formal PC consultation (June 2012) - draft WP v4 Work Programme adoption & publication: 10 July 2012

Health theme Cross cutting topic relevant to the entire Health theme 0-1 - Boosting the translation of FP projects' results into innovative applications for health. FP7-Health-2013-INNOVATION-2 build on the results of projects funded under Health theme of FP6 & FP7. focus on specifications, testing and validation of results applicants must control the IPR to be used in their application New: SMEs must be from Member States or Associated Countries (conditions specified, further changes to come based on INNOV-2 call) Funding scheme: CP-FP, max. €6m/project. MS & AC SMEs only. SME-topic: min. 50% EC contribution to SMEs Indicative budget: €75 million

The Health theme 1: Biotechnology, generic tools and medical for technologies for human health 1.1 High-throughput research (closed) 1.2 Detection, diagnosis and monitoring 1.3 Suitability, safety and efficacy of therapies 1.4 Innovative therapeutic approaches and interventions

Area 1.2 Detection, Diagnosis and Monitoring 37

Activity 1 Biotech, tools & technologies 1.2 – Detection, Diagnosis & Monitoring 1.2-1 - Development of imaging technologies for therapeutic interventions in rare diseases. Funding scheme: CP-FP, max. €6m/project. SME-topic: min. 30% EC contribution to SMEs

Area 1.3 Suitability, Safety and Efficacy of Medicines 39

Activity 1 Biotech, tools & technologies 1.3 – Suitability, safety & efficacy of medicines 1.3-1 - Modelling toxic responses in case studies for predictive human safety assessment. Funding scheme: CP-FP, max. €12m/project. Industry topic: min. 15% EC contribution to industry, incl. SMEs Only one proposal may be selected 1.3-2 - Innovative approaches to address adverse immune reactions to biomedical devices, implants & transplant tissues. Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs

Activity 1 Biotech, tools & technologies 1.3 – Suitability, safety & efficacy of medicines 1.3-3 - Safety and efficacy of therapeutic vaccines. Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs 1.3-4 - Development of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines. Funding scheme: CP-FP, max. €6m/project. New: max. 3 years SME topic: min. 30% EC contribution to SMEs

Area 1.4 Innovative therapeutic approaches and interventions 42

Activity 1 Biotech, tools & technologies 1.4-1 - Controlling differentiation and proliferation in human stem cells intended for therapeutic use. Funding scheme: CP-FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs

The Health theme 2: Translating research for human health 2.1 Integrating biological data and processes: large-scale data gathering, systems biology 2.2 Research on the brain and related diseases, human development and ageing 2.3 Translational research in major infectious diseases: to confront major threats to public health 2.4 Translational research in other major diseases

Area 2.1.1 Large-scale data gathering 45

Activity 2 - Translating research for human health 2.1.1 – Large-scale data gathering 2.1.1-1 - Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes. Funding scheme: CP-IP, max. €12m/project. SME topic: min. 30% EC contribution to SMEs 2.1.1-2 - High impact research initiative on metagenomics for personalised medicine approaches. Funding scheme: IP, max. €30m/project; max. 1 project Industry topic: min. 30% EC contribution to industry, incl. SMEs Only one proposal may be selected

Research on the brain and brain related diseases Area 2.2.1 Research on the brain and brain related diseases 47

Activity 2 - Translating research for human health 2.2.1-1 - Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI) Funding scheme: CP-IP, max. €30m/project, one or more projects 2.2.1-2 - Development of effective imaging tools for diagnosis, monitoring and management of mental disorders Funding scheme: CP-FP, max. €6m/project Industry topic: min. 30% EC contribution to industry, incl. SMEs

Activity 2 - Translating research for human health 2.2.1 – The brain and brain disorders 2.2.1-3 - Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment Funding scheme: CP-FP, max. €6m/project SME topic: min. 15% EC contribution to SMEs 2.2.1-4 - Patho-physiology and therapy of epilepsy and epileptiform disorders Funding scheme: CP-IP, max. €12m/project SME topic: min. 15% EC contribution to SMEs 2.2.1-5 – Understanding and combating pain (NEW) Funding scheme: CP-FP, max. €6m/project

2.3.1 – Antimicrobial drug resistance Area 2.3 Translational research in major infectious diseases; to confront major threats to public health 2.3.0 – Cross cutting issues 2.3.1 – Antimicrobial drug resistance 2.3.2 – HIV/AIDS, malaria, tuberculosis (closed) 2.3.3 – Potentially new & re-emerging epidemics 2.3.4 – Neglected infectious diseases 50

Activity 2 - Translating research for human health 2.3.0 – Cross-cutting priorities 2.3.0-1 – Innovation in vaccines Funding scheme: CP-FP, max. €6m/project. SME topic: min. 30% EC contribution to SMEs

Activity 2 - Translating research for human health 2.3.1 – Anti-microbial drug resistance 2.3.1-1 – INNOVATION 2 Drugs and vaccines for infections that have developed or are at risk of developing significant antimicrobial resistance. New: SMEs must be from Member States or Associated Countries Funding scheme: CP-FP, max. €6m/project. MS & AC SMEs only. SME topic: min. 50% EC contribution to SMEs 2.3.1-2 - Stratified approaches to antibacterial and/or antifungal treatment Funding scheme: CP-FP, max. €6m/project.

Activity 2 - Translating research for human health 2.3.3 – Potentially new and re-emerging epidemics 2.3.3-1 – Clinical management of patients in severe epidemics. Funding scheme: IP, max. €24m/project; max. 1 project

Activity 2 - Translating research for human health 2.3.4 – Neglected infectious diseases 2.3.4-1 – Neglected infectious diseases of Central and Eastern Europe. Funding scheme: FP, max. €3m/project. 2.3.4-2 – Drug development for neglected parasitic diseases. Funding scheme: FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs

2.4.1 – Cancer Area 2.4 Translational research in other major diseases 2.4.2 – CVD 2.4.3 – Diabetes/obesity (closed) 2.4.4 – Rare diseases (closed) 2.4.5 – Chronic diseases (closed) 55

Activity 2 - Translating research for human health 2.4.1 – Cancer 2.4.1-1 – Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer. Funding scheme: CP-FP, max. €6m/project. 2.4.1-2 – Strengthening the cancer patient's immune system. Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs 2.4.1-3 - Investigator-driven supportive and palliative care clinical trials and observational studies. Funding scheme: CP-FP, max. €6m/project.

Activity 2 - Translating research for human health 2.4.2 – Cardiovascular diseases 2.4.2-1 – Discovery research to reveal novel targets for cardiovascular disease treatment. Funding scheme: CP-FP, max. €6m/project. SME topic: min. 30% EC contribution to SMEs 2.4.2-2 – Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases. Funding scheme: CP-FP, max. €6m/project. 2.4.2-3: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan. Funding scheme: CP-FP, Small €3m/project.

The Health Theme 3: Optimising the delivery of healthcare to European citizens 3.1 Translating clinical research into clinical practice 3.2 Quality, efficiency and solidarity of healthcare systems (closed) 3.3 Health promotion and prevention 3.4 International public health & health systems (closed)

Activity 3 Optimising the delivery of healthcare 3.1 – Translating clinical research into clinical practice 3.1-1 - Comparative Effectiveness Research (CER) in health systems and health services interventions. Funding scheme: CP-FP, max. €6m/project. 3.3 – Health promotion and prevention 3.3-1 - Social innovation for health promotion Funding scheme: CP-FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs

The Health theme 4: Actions across the Theme 4.1 Coordination & Support Actions across the theme 4.2 Responding to EU policy needs

Activity 4 Actions across the theme 4.1 – CSAs across the theme 4.1-1 –Supporting industrial participation in EU-funded research in the Health sector. Funding scheme: CA, max. €2m/project, up to one project 4.1-2 – Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation. Funding scheme: SA, max. €0.5m/project, one or more projects

Activity 4 Actions across the theme 4.1 – CSAs across the theme 4.1-3 - Support for Presidency events. Organisation of supporting actions and events associated to the Presidency of the European Union "…specifically from mid-2013 to 2015 Presidencies, …" Funding scheme: SA, max. €0.1m/project, one or more projects 4.1-4 - Preparing the future for health research and innovation. Funding scheme: SA, max. €0.5m/project, one or more projects    4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations. Funding scheme: CA, max. €2m/project, up to one project    4.1-6: Mapping chronic non-communicable diseases research activities Funding scheme: CA, max. €1m/project, up to one project

Activity 4 Actions across the theme 4.2 – Responding to EU policy needs 4.2-1 - Investigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems. Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs. 4.2-2 - Adverse drug reaction research. Funding scheme: CP-FP, max. €3m/project. SME topic: min. 15 % EC contribution to SMEs. 4.2-3 - New methodologies for clinical trials for small population groups. Funding scheme: CP-FP, max. €3m/project.

All proposals must address these questions. Ethics: overview (1) Two main questions asked on ethics:  The necessity to use i.e. personal data, animals, human tissue in order to achieve the scientific objectives set forth in the proposal. Is there an alternative ?  Benefit/burden balance of the research project. What will be the impact of this research, not only regarding scientific advance, but also in terms of human dignity as well as social and cultural impact ? All proposals must address these questions.

Ethics: overview (2) Applicants must first identify key ethical issues raised by their proposals and explain how they will address them. The main issues are: Informed Consent Research on Human embryos/foetuses Data Protection and Privacy Research on Animals (the ‘3Rs’: Reduce, Replace, Refine) Research involving Developing Countries Dual use (research that could have military applications) 3 areas are excluded from funding: - Human reproductive cloning - Intentional germ line modification (except research relating to cancer of the gonads which can be funded) - Creation of human embryos for research or stem cell procurement (including by means of somatic cell nuclear transfer)

5. Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…

Other funding opportunities for health research within the Cooperation Specific Programme

Other funding opportunities for health research within the KBBE theme - 2013 Call identifier: FP7-KBBE-2013-7 Proposal submission and evaluation: one-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 5 February 2013 at 17:00 (Brussels local time) Indicative budget: EUR 680 million from the 2013 budget pocaterra@apre.it – cataldi@apre.it Call 7(WP2013) • Research and Innovation for the benefit of society, with a challenges driven approach to maximize the impact of research funded by the EU • 4 main challenges: the main pillars of bio-economySustainable 1) Agriculture and Forestry 2) Safe and Sustainable Food and Health Diets 3) Unlocking the potential of Aquatic Living Resources 4) Sustainable and Competitive Bio-based Industries • Broader topics in terms of budget and research developed, leaving greater freedom to the research community

Area 2.2.1 – Consumers Impact of food and nutritional behaviour, lifestyle and the socio-economic environment on depression and proposed remedial actions (LCP, Up to one project ) Area 2.2.2 -Nutrition New technologies to study brain function in relation to eating behaviours and mental well-being (LCP, Up to one project ) Factors influencing the human gut microbiome and its effect on the development of diet related diseases and brain development (LCP, Up to one project )

KBBE topics KBBE.2013.2.1-01: Impact of food and nutritional behaviour, lifestyle and the socioeconomic environment on depression and proposed remedial actions (Max 1 CP-IP. Max EC contribution: 6 M€) KBBE.2013.2.2-01: New technologies to study brain function in relation to eating Behaviour (Max 1 CP-IP. Max EC contribution: 9 M€) KBBE.2013.2.2-02: Factors influencing the human gut microbiome and its effect on the development of diet-related diseases and brain development (Max 1 CP-IP. Max EC contribution: 9 M€) KBBE.2013.2.2-03: Food-based solutions for eradication of vitamin D deficiency and health promotion throughout the life cycle (Max 1 CP-IP. Max EC contribution: 6 M€)

Other funding opportunities for health research within the ICT theme - 2013 BUDGET 1455 € Million deangelis@apre.it mercurio@apre.it APERTURA DEADLINE FP7-ICT-2013-10 10 Luglio 2012 15 Gennaio 2013 (734M€ from budget 2013) FP7-ICT-2013-11 18 Settembre 2012 16 Aprile 2013 (242M€ from budget 2013) FP7-2013-NMP-ICT-FoF 4 Dicembre 2012 (70M€ from budget 2013) FP7-2013-NMP-ENV-ENERGY-ICT-EeB 4 December 2012 (40M€ from budget 2013) FP7-2013-ICT-GC FP7-ICT-2013-SME-DCA 15 Gennaio 2013 (20M€ from budget 2013) FP7-ICT-2013-FET-F 23 Ottobre 2012 (100M€ from budget 2013) FP7-ICT-2013-C 12 Marzo 2013 (50M€ from budget 2013) FP7-ICT-2013-X 12 Settembre 2012 29 Gennaio 2013 (15M€ from budget 2013) FP7-ICT2013-EU-Japan 2 Ottobre 2012 29 Novembre 2012 (9M€ from budget 2013) FP7-ICT2013-EU-Brasil 24 Ottobre 2012 (4M€ from budget 2013) WP2013 will support the European Innovation Partnerships on Active and Healthy Ageing (EIP AHA) on Personalized health, active ageing, and independent living ICTs have a catalytic impact in three key areas: Productivity and innovation, by facilitating creativity and management Modernisation of public services, such as health, education and transport. Advances in science and technology, by supporting cooperation and access to information.

Challenge 5: ICT for Health, Ageing Well, Inclusion and Governance: Personalized health, active ageing, and independent living Personalized Guidance Services for lifestyle management and disease prevention. Personalized Guidance Services for management of co-morbidities and integrated care. Personalized Services for Independent Living and Active Ageing. Coordination and Support Actions. Virtual Physiological Human Clinical proof of concept of patient specific computer based models Personal Health Forecasting. Coordination and Support Action to develop an RTD roadmap preparing the ground for in-silico clinical trials ICT for smart and personalised inclusion Accessible and intuitive solutions for personalised interfaces to smart environments and innovative services.

Other funding opportunities for health research within the NMP theme - 2013 Work Programme 2013 Priorities desole@apre.it; borgna@apre.it PPPs (Green Cars, Factories of the Future Energy Efficient Buildings): ~ 36% Cross cutting innovation : ~12% Application-specific innovation : ~26% Raw Materials: ~3% Energy : ~5% Environment/Sustainability: ~9% Health and safety: ~9% NMP.2013.1.2-2 Nanotherapeutics to treat bacterial infectious diseases NMP.2013.2.2-1 Biomaterials for Advanced Therapies and Medical Devices in the neurological/neuromuscular or cardiovascular fields NMP.2013.2.2-2 Biomaterials: Imaging and rapid precise prototyping technology for custom made scaffolds – coordinated call with China

Other funding opportunities for health research within the ENV theme - 2013 Call identifier: FP7-ENV-2013-two stage Proposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 16 October 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 335.51 million from the 2013 budget materia@apre.it; dirosa@apre.it CHALLENGE 6.4 PROTECTING CITIZENS FROM ENVIRONMENTAL HAZARDS ENV.2013.6.4-1 Assessing individual exposure to environmental stressors and predicting health outcomes: paving the way for an EU-wide assessment (CP, Up to one project ) ENV.2013.6.4-2 Closing gaps of knowledge and reducing exposure to electromagnetic fields (EMF) (CP, Up to one project )

Other funding opportunities for health research within the SSH theme - 2013 Call identifier: FP7-SSH-2013-2 Proposal submission and evaluation: one-stage procedure. Date of publication: 12 July 2012 Deadline for stage 1 proposals: 31 January 2013 at 17.00.00 Brussels local time Indicative budget: EUR 72 000000 adunmo@apre.it; longo@apre.it Draft Work Programme 2013: SSH.2013.1.3-1 The impact of ageing societies on public finances in Europe Health care, SSH.2013.3.2-2. Early childhood education and care and the cost of inequities SSH.2013.3.2-3. The impact of the third sector on socio-economic development in Europe

Other funding opportunities for health research within the SPACE theme - 2013 Call identifier: FP7-SPACE-2013-1 Proposal submission and evaluation: one-stage procedure. Date of publication: 12 July 2012 Deadline: 21 November 2012, at 17.00.00, Brussels local time Indicative budget: EUR 126 million adunmo@apre.it Research and development on next generation products and service lines derived from space-borne data in conjunction with in-situ data is to be targeted Activities could target applications on areas like: Health services, or monitoring conditions for vector borne diseases (…) Earth-analogue research preparing for space exploration

6. Other EU funding opportunities for Health researchers

7. Sources of information and partners

www.HealthCompetence.eu An open, pan-European infrastructure for information on research projects & results within Health Science

HEALTH-NCP-NET http://www.healthncpnet.eu Your Support Network

[FIND A PARTNER]

Pagina Salute, Sito APRE www.apre.it/ricerca-europea/VIIPQ/Cooperazione/Salute/Bandi.htm CORDIS: CORDIS: http://cordis.europa.eu/fp7/health/ Fitforhealth: www.fitforhealth.eu Healthncpnet: www.healthncpnet.eu Healthcompentence: http://www.healthcompetence.eu/converis/publicweb/area/1353

PRESENTAZIONE IN 2 STAGE

4. Key issues for success

Advice for submission & evaluation (1) Basics Eligibility issues - funding scheme, number of partners (esp. for SICA), funding limits, deadlines Scope of proposal with respects to topic (Relevance) “The topic, the whole topic and nothing but the topic ” also pay attention to introduction in work programme and any specific requirements for industry or international participation Size and composition of the consortium - beyond the minimum rules, there are no constraints: bring together the competences needed to do the job. No bonus points for “political correctness” or large consortia

Advice for submission & evaluation (2) Basics Address all 3 criteria – be explicit to evaluators Address the Ethics issues Clear requirements for information on ethics issues* - you must explain what the issues are in the proposal - and how will you manage them Failing to do so can delay negotiation or even exclude a proposal. Respect basic rules and guidelines - font size (legibility) and page number limitations (excess pages will not be considered in the evaluation) *Guide for Applicants, Annex 4, section 4.

Key factors for success in applying for FP7 funding Competition is tough : only the best projects get funded the proposal must address the topic and the work programme (not wishful thinking) the consortium of partners must be excellent and competent for the tasks (select the right partners) the proposal must address all 3 criteria, convince the evaluators (don’t rely on reputation) and, of course, respect the basic rules. (deadlines, n° of participants, ceilings, length, ethics…)

Thanks for your attention ! Health NCP for ITALY APRE, Agenzia per la promozione della Ricerca Europea Via Cavour 71, Roma buonocore@apre.it; bergonzi@apre.it